Vergoeding 2018-2022 voor ATC-subgroep C09CA : Angiotensine-ii-antagonisten
- Raming voor de totale Zvw-populatie
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| C09CA01 Losartan (Cozaar ®) | 3.059.100 | 5.519.600 | 5.677.800 | 4.900.000 | 5.509.800 |
| C09CA02 Eprosartan (Teveten ®) | 363.030 | 113.450 | 48.291 | 52.318 | 51.817 |
| C09CA03 Valsartan (Diovan ®) | 3.565.200 | 2.708.800 | 2.551.800 | 2.974.500 | 3.430.100 |
| C09CA04 Irbesartan (Aprovel ®) | 2.643.100 | 4.293.900 | 4.182.000 | 3.741.100 | 3.580.400 |
| C09CA06 Candesartan (Atacand ®) | 1.209.900 | 1.778.500 | 2.006.600 | 2.004.100 | 2.115.700 |
| C09CA07 Telmisartan (Micardis ®) | 776.110 | 1.285.900 | 1.440.600 | 1.223.700 | 1.283.600 |
| C09CA08 Olmesartan (Olmetec ®) | 692.860 | 584.950 | 825.340 | 648.970 | 634.600 |
| Totaal | 12.309.300 | 16.285.100 | 16.732.431 | 15.544.688 | 16.606.017 |